Ms Helen Wray
CaptixBioTM is investing in collaborative projects to support the innovative application of cell and tissue technologies to improve disease management and ultimately deliver a widely accessible cure for Type 1 diabetes that does not require lifelong immuno-suppression therapy.
Captix Biomedical Pty Ltd
Managing DirectorDr Michelle Zajac
Cancer Therapeutics CRC (CTx) is in the business of finding cures for cancer. It was founded in 2007 and received an initial seven years of funding from the Cooperative Research Centre (CRC) Programme. It is a collaborative partnership of leading research institutes, universities and commercial enterprises that translates Australia’s innovative research discoveries into new cancer drugs ready for clinical development.